NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference

Rhea-AI Summary

NewAmsterdam Pharma (Nasdaq: NAMS), a late-stage clinical biopharmaceutical company focused on developing oral, non-statin medicines for cardiovascular disease patients with elevated LDL-C, has announced its participation in the Guggenheim SMID Cap Biotech Conference.

The company's Chief Financial Officer, Ian Somaiya, will engage in a fireside chat on Wednesday, February 5, 2025, at 10:00 a.m. ET. Investors and interested parties can access the live webcast through NewAmsterdam Pharma's investor relations website at ir.newamsterdampharma.com. An archived replay will be available on the company's website following the live presentation.

News Market Reaction

-3.12%

1 alert

-3.12% News Effect

On the day this news was published, NAMS declined 3.12%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

NAARDEN, The Netherlands and MIAMI, Jan. 29, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer of NewAmsterdam Pharma, will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 10:00 a.m. ET.

A live webcast of the fireside chat will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived replay will be available on the Company’s website.

About NewAmsterdam

NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com

Media Contact
Spectrum Science on behalf of NewAmsterdam
Jaryd Leady
P: 1-856-803-7855
jleady@spectrumscience.com

Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
austin.murtagh@precisionaq.com

FAQ

When is NewAmsterdam Pharma (NAMS) presenting at the Guggenheim SMID Cap Biotech Conference 2025?

NewAmsterdam Pharma will present at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 10:00 a.m. ET.

How can investors watch NewAmsterdam Pharma's (NAMS) Guggenheim Conference presentation?

Investors can watch the live webcast through NewAmsterdam Pharma's investor relations website at ir.newamsterdampharma.com. An archived replay will also be available after the presentation.

What type of medicines is NewAmsterdam Pharma (NAMS) developing?

NewAmsterdam Pharma is developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C, particularly for those who find existing therapies ineffective or poorly tolerated.

Who will represent NewAmsterdam Pharma (NAMS) at the Guggenheim SMID Cap Biotech Conference?

Ian Somaiya, Chief Financial Officer of NewAmsterdam Pharma, will represent the company and participate in a fireside chat at the conference.